Label

How We Work

Grant

Back

Print

Janssen Vaccines & Prevention B.V.


October 2016
to assess safety and tolerability of different vaccine regimens with Ad26.Mos4.HIV, Ad26.Mos.HIV and Clade C gp140 and immunogenicity between the different vaccine regimens with Ad26.Mos4.HIV, Ad26.Mos.HIV and Clade C gp140
$4,472,467
75
HIV
GLOBAL|AFRICA
Global Health
2333 CP Leiden, Zuid-Holland

Visit Our Blog